Patient preferences in treatment options of ulcerative colitis: a discrete choice experiment

被引:6
|
作者
Straatmijer, Tessa [1 ,2 ]
van den Akker-van Marle, M. Elske [3 ]
Ponsioen, Cyriel Y. [2 ]
van der Horst, Danielle [4 ]
Scherpenzeel, Menne P. M. [4 ]
Duijvestein, Marjolijn [5 ]
van der Meulen-de Jong, Andrea E. [1 ]
机构
[1] Leiden Univ, Med Ctr, Dept Gastroenterol & Hepatol, Leiden, Netherlands
[2] Univ Amsterdam, Amsterdam Gastroenterol Endocrinol Metab AGEM Res, Dept Gastroenterol & Hepatol, Amsterdam UMC, Amsterdam, Netherlands
[3] Leiden Univ, Med Ctr, Dept Biomed Data Sci, Sect Med Decis Making, Leiden, Netherlands
[4] Crohn & Colitis NL, Woerden, Netherlands
[5] Radboudumc, Dept Gastroenterol & Hepatol, Nijmegen, Netherlands
关键词
Patient preferences; treatment; ulcerative colitis; CONJOINT-ANALYSIS; HEALTH-CARE; PARTICIPATION; QUALITY;
D O I
10.1080/00365521.2023.2286191
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
IntroductionSince the number of medical treatment options for Ulcerative Colitis (UC) has expanded over the last decades, patients and physicians face challenges regarding decisions about the medication options. We aimed to identify patients' preferences about their UC treatment options in the Netherlands. Furthermore, we assessed after how many failed treatment options, patients are willing to consider surgical treatment.MethodsWe conducted a web-based, multicenter, discrete choice experiment (DCE) among adult UC patients. Patients were repeatedly asked to choose between two hypothetical medicinal treatment options. The choice tasks were based on administration route, administration location, chance of symptom reduction (on short and long term) and chances on infection and other adverse events. Data were analyzed by using Hierarchical Bayes estimation.ResultsA total of 172 UC patients participated in the DCE. More than half were anti-TNF experienced (52.9%). The chance of symptom reduction after one year (relative importance (RI) 27.7 (95% CI 26.0-29.4)) was most important in choosing between medicinal treatments, followed by the chance of infection (RI 22.3 (21.4 - 23.3)) and chance of symptom reduction after eight weeks (RI 19.5 (18.3 - 20.6)). Considering surgical treatment, nineteen patients (14.3%) would not even consider surgery after failing eight treatment options without any new available therapies left. Nine patients would consider surgery before trying any treatment options.ConclusionWe found that symptom reduction after one year was the most important attribute in choosing between treatments in UC patients. These outcomes can help understand the trade-offs and preferences of UC patients.
引用
收藏
页码:288 / 295
页数:8
相关论文
共 50 条
  • [1] Patient preferences for treatment in steroid resistant ulcerative colitis - a discrete-choice experiment
    Wickramasekera, Nyantara
    Coates, Elizabeth
    Barr, Amy
    Lee, Matthew J.
    Blackwell, Sue
    Bedford, Hugh
    Dames, Nicola
    Sebastian, Shaji
    Probert, Christopher
    Shackley, Phil
    Lobo, Alan J.
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2022, 57 (07) : 797 - 806
  • [2] Patient preferences in medication to treat Ulcerative Colitis: a discrete choice experiment
    Straatmijer, T.
    Van den Akker-Van Marle, E.
    Van der Horst, D.
    Scherpenzeel, M.
    Duijvestein, M.
    Van der Meulen, A.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 818 - 818
  • [3] Patient Preferences for Ulcerative Colitis Treatment in the Middle East Region: A Discrete-Choice Experiment
    Alharbi, Othman
    Abu Farsakh, Niazy
    Al-Awadhi, Sameer
    Al-Taweel, Talal
    Mikhail, Inas
    Batwa, Faisal
    Bedran, Khalil
    Balkan, Dilara
    Gunay, Levent Mert
    Cappelleri, Joseph C.
    Boeri, Marco
    Leach, Colton
    Habjoka, Sara
    Mosli, Mahmoud
    GASTRO HEP ADVANCES, 2024, 3 (02): : 190 - 200
  • [4] Patient Preferences for Cholesterol Treatment Options: A Discrete Choice Experiment
    Lewey, Jennifer
    Choudhry, Niteesh K.
    Gagne, Joshua J.
    Avorn, Jerry
    Najafzadeh, Mehdi
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 : 157 - 157
  • [5] Patient preferences in steroid resistant ulcerative colitis - a discrete choice experiment survey
    Wickramasekera, N.
    Shackley, P.
    Coates, E.
    Barr, A.
    Lee, M.
    Blackwell, S.
    Bedford, H.
    Dames, N.
    Sebastian, S.
    Probert, C.
    Lobo, A.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S249 - S249
  • [6] PATIENT PREFERENCES FOR CHOLESTEROL TREATMENT OPTIONS: A DISCRETE CHOICE EXPERIMENT (DCE)
    Lewey, J.
    Choudhry, N. K.
    Gagne, J. J.
    Avom, J.
    Najafzadeh, M.
    VALUE IN HEALTH, 2017, 20 (05) : A274 - A274
  • [7] PATIENT PREFERENCES FOR ULCERATIVE COLITIS TREATMENT IN THE MIDDLE EAST REGION: RESULTS FROM A DISCRETE-CHOICE EXPERIMENT
    Alharbi, Othman
    Abu Farsakh, Niazy
    Alawadhi, Sameer
    Al-Taweel, Talal
    Mikhail, Inas
    Batwa, Faisal
    Bedran, Khalil
    Balkan, Dilara
    Cappelleri, Joseph C.
    Boeri, Marco
    Habjoka, Sara
    Mosli, Mahmoud
    GASTROENTEROLOGY, 2022, 162 (07) : S688 - S689
  • [8] Patient preferences regarding treatment options for Waldenstrom's macroglobulinemia: A discrete choice experiment
    Amaador, Karima
    Nieuwkerk, Pythia T.
    Minnema, Monique C.
    Kersten, Marie Jose
    Vos, Josephine M., I
    CANCER MEDICINE, 2023, 12 (03): : 3376 - 3386
  • [9] Patient and Oncology Nurse Preferences for the Treatment Options in Advanced Melanoma A Discrete Choice Experiment
    Liu, Frank Xiaoqing
    Witt, Edward A.
    Ebbinghaus, Scot
    Beyer, Grace DiBonaventura
    Basurto, Enrique
    Joseph, Richard W.
    CANCER NURSING, 2019, 42 (01) : E52 - E59
  • [10] Patient Preferences for First-Line Oral Treatment for Mild-to-Moderate Ulcerative Colitis A Discrete-Choice Experiment
    Hodgkins, Paul
    Swinburn, Paul
    Solomon, Dory
    Yen, Linnette
    Dewilde, Sarah
    Lloyd, Andrew
    PATIENT-PATIENT CENTERED OUTCOMES RESEARCH, 2012, 5 (01): : 33 - 44